FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Rita Nahta

Research Profile

Disorders

Breast Neoplasms

Chemicals & Drugs

Physiology

Anatomy

Tumor Cell Line

Procedures

Clinical Trials as Topic

Co-author Network

Publications

TOP 3
S S Gayle; M C Buss; R C Castellino; Rita Nahta
MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1.
Samantha E Griner; Jayashree P Joshi; Rita Nahta
Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion.
Kevin Yehl; R Brian Dyer; Brandon L Greene; Jayashree P Joshi; Rita Nahta; khalid salaita
Catalytic deoxyribozyme-modified nanoparticles for RNAi-independent gene regulation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Rita Nahta (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: S S Gayle; M C Buss; R C Castellino; Rita Nahta
MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1.
Current medicinal chemistry 2013;20(19):2486-99.
2013: Samantha E Griner; Jayashree P Joshi; Rita Nahta
Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion.
Biochemical pharmacology 2013;85(1):46-58.
2012: Kevin Yehl; R Brian Dyer; Brandon L Greene; Jayashree P Joshi; Rita Nahta; khalid salaita
Catalytic deoxyribozyme-modified nanoparticles for RNAi-independent gene regulation.
ACS nano 2012;6(10):9150-7.
2012: Joong Sup Shim; Kristin Beebe; Inkyu Han; Rita Nahta; Len Neckers; Rajini Rao; Jun O Liu
Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.
Journal of the National Cancer Institute 2012;104(20):1576-90.
2012: Rita Nahta; Ruth M O'Regan
Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.
Breast cancer research and treatment 2012;135(1):39-48.
2012: Sylvia S Gayle; Samuel L M Arnold; Ruth M O'Regan; Rita Nahta
Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Anti-cancer agents in medicinal chemistry 2012;12(2):151-62.
2012: Rita Nahta
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer.
ISRN oncology 2012;2012():428062.
2012: Rita Nahta
Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.
Chemotherapy research and practice 2012;2012():648965.
2011: Jayashree P Joshi; Nicole E Brown; Samantha E Griner; Rita Nahta
Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
Biochemical pharmacology 2011;82(9):1090-9.
2011: Yuhua Zhao; Richard Voellmy; Glenn L Wilson; Yun Wu; Jieqing Chen; Yan Ding; Oystein Fodstad; Susan P LeDoux; Wensheng Lin; Yifeng Lin; Bolin Liu; Hao Liu; Zixing Liu; Rita Nahta; Janet E Price; Ming Tan
Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism.
Cancer research 2011;71(13):4585-97.
2011: Tuba Ozbay; Rita Nahta
Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines.
Breast cancer : basic and clinical research 2011;5():143-54.
2010: Rita Nahta; Ruth M O'Regan
Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Clinical breast cancer 2010;10 Suppl 3():S72-8.
2010: Tuba Ozbay; Donald L Durden; Tongrui Liu; Ruth M O'Regan; Rita Nahta
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
Cancer chemotherapy and pharmacology 2010;65(4):697-706.
2009: Danica L Rowe; Tuba Ozbay; Ruth M O'Regan; Rita Nahta
Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin.
Breast cancer : basic and clinical research 2009;3():61-75.
2008: Danica L Rowe; Tuba Ozbay; Laura M Bender; Rita Nahta
Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer.
Molecular cancer therapeutics 2008;7(7):1900-8.
2008: Tuba Ozbay; Rita Nahta
A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells.
Molecular cancer research : MCR 2008;6(6):1052-8.
2008: Fabrice Andre; Rita Nahta; R Conforti; Thomas Boulet; M Aziz; Linda X H Yuan; Franck Meslin; Marc Spielmann; Gorana Tomasic; Lajos Pusztai; Gabriel N Hortobagyi; Stefan Michiels; Suzette Delaloge; Francisco J Esteva
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):315-20.
2008: Laura M Bender; Rita Nahta
Her2 cross talk and therapeutic resistance in breast cancer.
Frontiers in bioscience : a journal and virtual library 2008;13():3906-12.
2007: Rita Nahta; Francisco J Esteva
Trastuzumab: triumphs and tribulations.
Oncogene 2007;26(25):3637-43.
2007: Rita Nahta; Linda X H Yuan; Yi Du; Francisco J Esteva
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
Molecular cancer therapeutics 2007;6(2):667-74.
2007: Hiroaki Itamochi; Junzo Kigawa; Yasunobu Kanamori; Tetsuro Oishi; Chandra Bartholomeusz; Rita Nahta; Francisco J Esteva; Nour Sneige; Naoki Terakawa; Naoto T Ueno
Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy.
Molecular cancer therapeutics 2007;6(1):227-35.
2006: Rita Nahta; Linda X H Yuan; Derek J Fiterman; LI Zhang; W Fraser Symmans; Naoto T Ueno; Francisco J Esteva
B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells.
Molecular cancer therapeutics 2006;5(6):1593-601.
2006: Rita Nahta; Dihua Yu; Mien-Chie Hung; Gabriel N Hortobagyi; Francisco J Esteva
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nature clinical practice. Oncology 2006;3(5):269-80.
2006: Rita Nahta; Francisco J Esteva
Herceptin: mechanisms of action and resistance.
Cancer letters 2006;232(2):123-38.
2006: Rita Nahta; Francisco J Esteva
HER2 therapy: molecular mechanisms of trastuzumab resistance.
Breast cancer research : BCR 2006;8(6):215.
2005: Rita Nahta; Linda X H Yuan; Bing Zhang; Ryuji Kobayashi; Francisco J Esteva
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
Cancer research 2005;65(23):11118-28.
2004: Wei Wang; Rita Nahta; Gudrun Huper; Jeffrey R Marks
TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein.
Molecular cancer research : MCR 2004;2(8):442-52.
2004: Rita Nahta; Takeshi Takahashi; Naoto T Ueno; Mien-Chie Hung; Francisco J Esteva
P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.
Cancer research 2004;64(11):3981-6.
2004: Rita Nahta; Mien-Chie Hung; Francisco J Esteva
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.
Cancer research 2004;64(7):2343-6.
2004: Francisco J Esteva; Aysegul A Sahin; Terry L Smith; Ying Yang; Lajos Pusztai; Rita Nahta; Thomas Buchholz; Aman U Buzdar; Gabriel N Hortobagyi; Sarah S Bacus
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Cancer 2004;100(3):499-506.
2004: Rita Nahta; Francisco J Esteva
In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.
Cancer chemotherapy and pharmacology 2004;53(2):186-90.
2003: Francisco J Esteva; Aysegul A Sahin; George Z Rassidakis; Linda X H Yuan; Terry L Smith; Ying Yang; Michael Z Gilcrease; Massimo Cristofanilli; Rita Nahta; Lajos Pusztai; Francois Claret
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5652-9.
2003: Rita Nahta; Francisco J Esteva
HER-2-targeted therapy: lessons learned and future directions.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5078-84.
2003: Rita Nahta; Francisco J Esteva
Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer.
Seminars in oncology 2003;30(5 Suppl 16):143-9.
2003: Rita Nahta; Sally Trent; Chuanwei Yang; Emmett V Schmidt
Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.
Cancer research 2003;63(13):3626-31.
2003: Rita Nahta; Gabriel N Hortobagyi; Francisco J Esteva
Novel pharmacological approaches in the treatment of breast cancer.
Expert opinion on investigational drugs 2003;12(6):909-21.
2003: Rita Nahta; Gabriel N Hortobagyi; Francisco J Esteva
Signal transduction inhibitors in the treatment of breast cancer.
Current medicinal chemistry. Anti-cancer agents 2003;3(3):201-16.
2003: Rita Nahta; Gabriel N Hortobágyi; Francisco J Esteva
Growth factor receptors in breast cancer: potential for therapeutic intervention.
The oncologist 2003;8(1):5-17.
2002: Rita Nahta; J Dirk Iglehart; Bettina Kempkes; Emmett V Schmidt
Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.
Cancer research 2002;62(8):2267-71.
1999: Q Dong; Stewart P Johnson; O Michael Colvin; Nancy S Bullock; C Kilborn; G Runyon; D M Sullivan; J Easton; Darell D Bigner; Rita Nahta; J Marks; Paul Modrich; Henry S Friedman
Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR).
Cancer chemotherapy and pharmacology 1999;43(1):73-9.